Applications of 16-Dehydroprogesterone in Industrial Manufacturing

As a specialized manufacturer of 16-Dehydroprogesterone, we provide this intermediate-grade raw material for targeted industrial use. The applications outlined below reflect established, high-volume downstream segments based on clear processing standards and regulatory requirements. All scenarios focus on differentiated, real-world industrial demand, with practical formulation, compliance, and end-product details for each sector.

1. Synthesis of Corticosteroid Pharmaceutical APIs

Pharmaceutical manufacturers use 16-Dehydroprogesterone as a critical intermediate during the multi-step synthesis of corticosteroid active pharmaceutical ingredients (APIs). The compound functions as a select precursor for introducing specific chemical modifications at C16 during the construction of glucocorticoid and mineralocorticoid structures. Downstream processes rely on repeatable conversion kinetics, with close process controls on impurity profiles and stereoisomer ratios. Precise additions during batch processing reduce side reactions and enhance downstream API purification efficiency, supporting consistent manufacturing of high-purity finished corticosteroids destined for regulated markets.

Industry compliance standards

• ICH Q7, EU GMP Part II for API manufacturing
• Ph. Eur., USP, JP monographs for corticosteroids
• EMA, US FDA cGMP API guidelines
• ISO 9001-certified API supply chain management

Typical usage ratio

• Standard intermediate charge is 0.7–1.1 molar equivalent per target corticosteroid API molecule, adjusted according to reaction yield and pathway optimization goals

Downstream process integration

• Direct addition into the steroidal core skeleton during the oxidation stage in API multi-step synthesis (e.g., before C16-hydroxylation or side-chain cleavage)

Final product types

• Betamethasone and Dexamethasone APIs
• Prednisolone and related glucocorticoids
• Fludrocortisone and other synthetic mineralocorticoids

2. Intermediate for Progestin Drug Manufacturing

Industrial-scale progestin plants utilize 16-Dehydroprogesterone within dedicated synthesis routes for certain second-generation oral contraceptive APIs and hormonal therapies. Its structured double bond at C16 allows site-specific catalytic reduction or functionalization, creating the desired progestin core with optimal receptor binding properties. Controlled incorporation during process chemistry steps enables route flexibility for adjusting to batch purity and target specification for different finished drug products. These facilities adhere to mandatory process validation and full batch traceability to ensure patient safety and regulatory acceptance.

Industry compliance standards

• ICH Q11, Q3A-B (Impurity & Control of Drug Substance)
• WHO GMP for hormonal API production
• Dedicated facility segregation per EU EudraLex Vol. 4
• Relevant local pharmacopoeial standards where APIs will be marketed

Typical usage ratio

• Employed at 0.4–0.6 molar equivalents relative to target progestin backbone, with fine adjustments to drive specific isomer yields

Downstream process integration

• Integrated in ring modification and selective hydrogenation steps following the initial progesterone synthesis, typically in glass-lined reactor vessels

Final product types

• Medroxyprogesterone acetate and derivatives
• Chlormadinone acetate
• Lynestrenol and similar contraceptive APIs

3. Raw Material for Veterinary Steroid Formulations

Veterinary medicine producers incorporate 16-Dehydroprogesterone as a key raw material for the synthesis of specialty steroids used in animal reproductive health and anti-inflammatory injection drug formulations. Its defined double-bond structure enables precise transformation via selective reduction, supporting high batch consistency of the veterinary steroid final actives. These operations emphasize cross-contamination controls and veterinary-only regulatory documentation, given species-specific requirements and market segmentation unique to animal health applications.

Industry compliance standards

• VICH GL28 (Good Manufacturing Practice for APIs in Veterinary Medicinal Products)
• US FDA 21 CFR Part 514 (New Animal Drug Applications)
• National regulations on veterinary drugs (e.g., China VDCR)
• Strict in-house cross-contamination SOPs aligned with GMP+ feed safety requirements if used in medicated premix lines

Typical usage ratio

• Applied at 0.8–1.0 molar equivalents in catalyst-driven reductions, tailored by target animal species and injection formulation purity

Downstream process integration

• Fed into the functionalization and esterification stage post-progesterone precursor reaction, with rigorous in-process QC checks pre-packaging

Final product types

• Veterinary injectable steroids for fertility management (e.g., medroxyprogesterone acetate)
• Formulations for estrus synchronization in cattle, swine, sheep

4. Reference Compound for Analytical and Research Standards

Producers of certified reference standards and analytical labs use high-purity 16-Dehydroprogesterone as a validated benchmarking compound for HPLC, GC, and MS method development in the steroid pharmaceutical industry. The well-characterized molecular structure and stability profile enable accurate calibration curves, system suitability tests, and impurity profiling across QC and stability testing protocols. These applications demand comprehensive certification, full traceability, and conformity to international laboratory quality systems for reference material production.

Industry compliance standards

• ISO 17034:2016 (General requirements for the competence of reference material producers)
• ISO/IEC 17025:2017 for analytical laboratories
• USP General Chapter <11> Reference Standards
• OECD Principles of Good Laboratory Practice (GLP)

Typical usage ratio

• Used at 0.1–1.0 mg/mL for API quantitative analytical methods; concentration fine-tuned based on detection limit and calibration linearity

Downstream process integration

• Direct dissolution into certified diluents to prepare primary analytical reference solutions, followed by distribution to in-house or customer QC labs

Final product types

• Certified Reference Materials (CRMs) in ampoule or vial formats
• Analytical control standards for pharmaceutical release testing
• System suitability kits for pharmaceutical quality control